Nisa Investment Advisors
ZVRA icon

Nisa Investment Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Nisa Investment Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9K Buy
1,247
+1,129
+957% +$12.6K ﹤0.01% 2274
2026
Q1 		$1.1K Sell
118
-734
-86% -$6.62K ﹤0.01% 2731
2025
Q4 		$7.63K Hold
852
– – ﹤0.01% 2335
2025
Q3 		$8.1K Hold
852
– – ﹤0.01% 2339
2025
Q2 		$7.51K Buy
852
+641
+304% +$5.2K ﹤0.01% 2367
2025
Q1 		$1.58K Buy
211
+93
+79% +$739 ﹤0.01% 2529
2024
Q4 		$984 Hold
118
– – ﹤0.01% 2690
2024
Q3 		$819 Hold
118
– – ﹤0.01% 2621
2024
Q2 		$578 Buy
+118
New +$559 ﹤0.01% 2654
2023
Q4 		– Sell
-2,500
Closed -$12.1K – 2766
2023
Q3 		$12.1K Buy
+2,500
New +$12.5K ﹤0.01% 2139
2022
Q1 		– Sell
-3,650
Closed -$26K – 2412
2021
Q4 		$26K Buy
+3,650
New +$32.6K ﹤0.01% 1881

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nisa Investment Advisors's ZVRA Position: Q2 2026 in Review

Nisa Investment Advisors increased its Zevra Therapeutics (ZVRA) stake by 957% in Q2 2026, buying an estimated $12.6K and bringing the position to 1,247 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2274.

Nisa Investment Advisors first reported a position in ZVRA in Q4 2021 and has held it in 11 quarters since. The position peaked at $26K in Q4 2021. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Nisa Investment Advisors held 1,247 shares of Zevra Therapeutics worth $17.9K as of Q2 2026.
  • Nisa Investment Advisors bought 1,129 Zevra Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Zevra Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2274 holding.
  • Nisa Investment Advisors first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • Nisa Investment Advisors's Zevra Therapeutics position peaked at $26K in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.